Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Preseptal and Orbital Cellulitis | OBN
Preseptal cellulitis (periorbital cellulitis) is infection of the eyelid and surrounding skin anterior to the orbital septum. Orbital cellulitis is infection of the orbital tissues posterior to the orbital septum. Either can be caused by an external focus of infection (eg, a wound),…
Nordic Pharma Introduces Lacrifill Canalicular Gel for Dry Eye
Nordic Pharma announced the commercial launch of Lacrifill Canalicular Gel, aimed at addressing dry eye disease in the United States. This novel therapy, Lacrifill, is a cross-linked hyaluronic acid derivative that has received clearance from the FDA. Its primary function…
J&J’s Nipocalimab Shows Promising Results in Sjögren’s Disease
Johnson & Johnson announced promising topline results from its Phase 3 VIVACITY study evaluating nipocalimab in adults with generalized myasthenia gravis (gMG), alongside findings from the Phase 2 DAHLIAS study in adults with Sjögren’s disease (SjD). Nipocalimab, an investigational treatment,…
New Device Targets Dry Eye and Beyond with Thermal Imaging
A groundbreaking innovation in ocular health assessment is on the horizon, as a new University of Waterloo spinoff company, ThermOcular AI, unveils its pioneering approach to eye temperature monitoring. Transforming Ocular Diagnostics Founded by vision science and engineering researchers from…
Teprotumumab Shows Long-Lasting Benefits for TED Patients
Research presented at ENDO 2024, the Endocrine Society’s annual meeting in Boston, Massachusetts, and published in the journal Thyroid, indicates that most patients with thyroid eye disease (TED) treated with teprotumumab did not require additional treatments nearly two years later.…
Beacon Therapeutics Initiates VISTA Trial for X-Linked RP
Beacon Therapeutics announced the treatment of the inaugural patient in its pivotal VISTA clinical trial with its lead asset, AGTC-501 (laruparetigene zovaparvovec), marking a significant advancement in the pursuit of combating X-Linked Retinitis Pigmentosa (XLRP). Objective of the VISTA Trial…
Robot Radiotherapy Could Improve Treatment for AMD
Researchers from King’s College London, in collaboration with doctors at King’s College Hospital NHS Foundation Trust, have achieved a breakthrough in treating a debilitating eye disease using a new robot system. This system targets wet neovascular age-related macular degeneration (AMD)…
Melatonin Use Linked to Reduced Risk of AMD
A recent study published online in JAMA Ophthalmology suggests that melatonin use is associated with a decreased risk of both the development and progression of age-related macular degeneration (AMD). Investigating the Association: A Retrospective Cohort Study Hejin Jeong, from the…
Skye Bioscience’s Next Steps After Glaucoma Trial Disappointment
Skye Bioscience’s phase 2a clinical trial of its SBI-100 ophthalmic emulsion in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT) has failed to meet its primary endpoint for lowering intraocular pressure (IOP). Consequently, the company announced its decision…
CAM360 AmnioGraft: BioTissue’s Ocular Surface Therapy
BioTissue announced the launch of CAM360 AmnioGraft (CAM360 AG), a new, hydrated, shelf-stable ‘Cryopreserved Amniotic Membrane’ (CAM) solution designed for treating dry eye and various ocular surface disorders. Initial shipments of the product have commenced, with nationwide availability expected by…